Download PDF
Nervenheilkunde 2006; 25(05): 351-358
DOI: 10.1055/s-0038-1626470
Originaler Artikel
Schattauer GmbH

Wie früh kann eine Schizophrenie erkannt und behandelt werden?

How early is it possible to detect and to treat schizophrenia?
N. Vasic
1   Universitätsklinikum Ulm, Abteilung Psychiatrie III (Ärztl. Direktor: Prof. Dr. med. Dr. phil. M. Spitzer)
,
R. C. Wolf
1   Universitätsklinikum Ulm, Abteilung Psychiatrie III (Ärztl. Direktor: Prof. Dr. med. Dr. phil. M. Spitzer)
› Author Affiliations
Further Information

Publication History

Publication Date:
19 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Schizophrenie ist eine lang andauernde und versorgungsintensive Erkrankung, die in ihrem Verlauf immer wieder kostenaufwändige stationäre Behandlungen notwendig macht. In den letzten Jahren mehren sich Hinweise darauf, dass ein frühzeitiges Erkennen und konsequentes Behandeln der Erkrankung, bestenfalls schon in der Prodromalphase, einen positiven Einfluss auf den weiteren Krankheitsverlauf sowie die hiermit verbundenen gesundheitlichen und medizinisch-ökonomischen Folgen haben kann. In diesem Beitrag werden evidenzbasiert die Konzepte und Methoden zur Früherkennung und -behandlung der Schizophrenie sowie die notwendigen Rahmenbedingungen und Umstände ihrer Implementierung in die Praxis dargestellt. Trotz bedeutender Fortschritte kann zum gegenwärtigen Zeitpunkt bezüglich der Früherkennung und -behandlung kein einheitliches Vorgehen empfohlen werden, sodass eine Entscheidung in der Praxis weiterhin individuell gefällt werden muss.

Summary

Schizophrenia isa long-lasting and care-intensive disease, making in its progression over and over costly hospital treatments inevitable. In the last few years increasing indications have emerged showing that early identification and forceful treatment of the disease, at best already in the prodromal phase, can have a positive impact on the further course of disease as well as on the herewith associated consequences concerning patients health and medical-economically aspects. In this article we present evidence-based concepts and methods for the early detection and treatment of schizophrenia as well as the necessary general conditions and framework for their realisation. In spite of the significant progress made in this field, a state-of-the-art procedure still has to be established. At present, diagnostic and therapeutic decisions must relay on individual parameters.

Schlüsselwörter

Schizophrenie - Prodromalphase - unbehandelte Psychose - Frühbehandlung

Keywords

Schizophrenia - prodrome - untreated psychosis - early intervention
 

  • Literatur

  • 1 Amminger GP, Edwards J, Brewer WJ, Harrigan S, McGorry PD. Duration of untreated psychosis and cognitive deterioration in first-episode schizophrenia. Schizophr Res 2002; 54: 223-30.
    CrossrefPubMedGoogle Scholar
  • 2 Birchwood M, McGorry P, Jackson H. Early intervention in schizophrenia. Br J Psychiatry 1997; 170: 2-5.
    CrossrefPubMedGoogle Scholar
  • 3 Browne S, Clarke M, Gervin M, Waddington JL, Larkin C, O’Callaghan E. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000; 176: 173-6.
    CrossrefPubMedGoogle Scholar
  • 4 Cannon M, Clarke MC. Risk for schizophrenia-broadening the concepts, pushing back the boundaries. Schizophr Res 2005; 79: 5-13.
    CrossrefPubMedGoogle Scholar
  • 5 Cannon M, Walsh E, Hollis C, Kargin M, Taylor E, Murray RM, Jones PB. Predictors of later schizophrenia and affective psychosis among attendees at a child psychiatry department. Br J Psychiatry 2001; 178: 420-6.
    CrossrefPubMedGoogle Scholar
  • 6 Cannon TD, Huttunen MO, Dahlstrom M, Larmo I, Rasanen P, Juriloo A. Antipsychotic drug treatment in the prodromal phase of schizophrenia. Am J Psychiatry 2002; 159: 1230-2.
    CrossrefPubMedGoogle Scholar
  • 7 Carbone S, Harrigan S, McGorry PD, Curry C, Elkins K. Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand 1999; 100: 96-104.
    CrossrefPubMedGoogle Scholar
  • 8 Clade H. Versorgungsforschung: Fallbeispiel Schizophrenie – Hohe soziale Kosten. Deutsches Ärzteblatt 2003; 08: 353.
    Google Scholar
  • 9 Cornblatt B, Lencz T, Corell C, Author A, Smith C. Treating the prodrome: naturalistic findings from the RAP program. Acta Psychiatr Scand 2002; 106 (suppl): 44.
    CrossrefPubMedGoogle Scholar
  • 10 Cornblatt BA. The New York high risk project to the Hillside recognition and prevention (RAP) program. Am J Med Genet 2002; 114: 956-66.
    CrossrefPubMedGoogle Scholar
  • 11 Cornblatt BA, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical?. Schizophr Res 2001; 51: 31-8.
    CrossrefPubMedGoogle Scholar
  • 12 Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. Am J Psychiatry 2000; 157: 60-6.
    CrossrefPubMedGoogle Scholar
  • 13 DeGrazia D. Ethical issues in early-intervention clinical trials involving minors at risk for schizophrenia. Schizophr Res 2001; 51: 77-86.
    CrossrefPubMedGoogle Scholar
  • 14 Deister A. SM. Verlauf schizophrener Psychosen. In: SM (Hrsg). Schizophrenie – Pathogenese, Diagnostik und Therapie. 1. ed,. Vol Bremen: UNIMED Verlag AG 2002: 79-90.
    Google Scholar
  • 15 DeQuardo JR. Pharmacologic treatment of firstepisode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 (Suppl. 19) 9-17.
    PubMedGoogle Scholar
  • 16 Edwards J, Maude D, McGorry PD, Harrigan SM, Cocks JT. Prolonged recovery in first-episode psychosis. Br J Psychiatry Suppl 1998; 172: 107-16.
    CrossrefPubMedGoogle Scholar
  • 17 Falloon IR, Kydd RR, Coverdale JH, Laidlaw TM. Early detection and intervention for initial episodes of schizophrenia. Schizophr Bull 1996; 22: 271-82.
    CrossrefPubMedGoogle Scholar
  • 18 Gaebel W, Moeller HJ. Kompetenznetz Schizophrenie. http://www.kompetenznetz-schizophrenie.de/rdkns/index.htm 2005
    PubMedGoogle Scholar
  • 19 Gottesman II. Schizophrenia epigenesis: past, present, and future. Acta Psychiatr Scand Suppl 1994; 384: 26-33.
    Google Scholar
  • 20 Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991; 41: 1-24.
    CrossrefPubMedGoogle Scholar
  • 21 Haas GL, Garratt LS, Sweeney JA. Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998; 32: 151-9.
    CrossrefPubMedGoogle Scholar
  • 22 Häfner H. Was ist Schizophrenie?. In: Was ist Schizophrenie?. Stuttgart Jena New York: Fischer Verlag; 1995
    Google Scholar
  • 23 Häfner HadHW. The course of schizophrenia in the light of modern follow-up studies: the ABC and WHO studies. Eur Arch Psychiatry Clin Neurosci 1999; 249: 14-26.
    PubMedGoogle Scholar
  • 24 Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993; 162: 80-6.
    CrossrefPubMedGoogle Scholar
  • 25 Hanssen M, Bak M, Bijl R, Vollebergh W, van Os J. The incidence and outcome of subclinical psychotic experiences in the general population. Br J Clin Psychol 2005; 44: 181-91.
    CrossrefPubMedGoogle Scholar
  • 26 Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD. The relationship between duration of untreated psychosis and outcome: An eightyear prospective study. Schizophr Res. 2005
    PubMedGoogle Scholar
  • 27 Heinssen RK, Perkins DO, Appelbaum PS, Fenton WS. Informed Consent in Early Psychosis Research: National Institute of Mental Health workshop, November 15, 2000. Schizophr Bull 2001; 27: 571-83.
    CrossrefPubMedGoogle Scholar
  • 28 Ho BC, Alicata D, Mola C, Andreasen NC. Hippocampus volume and treatment delays in first-episode schizophrenia. Am J Psychiatry 2005; 162: 1527-9.
    CrossrefPubMedGoogle Scholar
  • 29 Ho BC, Alicata D, Ward J, Moser DJ, O’Leary DS, Arndt S, Andreasen NC. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am J Psychiatry 2003; 160: 142-8.
    CrossrefPubMedGoogle Scholar
  • 30 Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in firstepisode schizophrenia. Am J Psychiatry 2000; 157: 808-15.
    CrossrefPubMedGoogle Scholar
  • 31 Hoff PSM. Psychotische Erkrankungen: Die psychiatriehistorische Perspektive. In: Schizophrenie – Pathogenese, Diagnostik und Therapie. 1. ed,. Vol Bremen: UNI-MED Verlag AG 2002: 20-34.
    Google Scholar
  • 32 Holzer L, Halfon O, Laget J. Intervention in adolescent psychosis risk. J Am Acad Child Adolesc Psychiatry 2005; 44: 512.
    CrossrefPubMedGoogle Scholar
  • 33 Huber G. Die Schizophrenien. In: Psychiatrie. Lehrbuch für Studierende und Ärzte. 5. ed,. Vol Stuttgart, New York: Schattauer; 1994: 252-386.
    Google Scholar
  • 34 Huber G, Gross G, Schuttler R. Schizophrenia. Clinical course and social psychiatric long term examinations of schizophrenic patients hospitalized in Bonn from 1945–1959. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1979; 21: 1-399.
    PubMedGoogle Scholar
  • 35 Jablensky A. The 100-year epidemiology of schizophrenia. Schizophr Res 1997; 28: 111-25.
    CrossrefPubMedGoogle Scholar
  • 36 Keshavan MS. Development, disease and degeneration in schizophrenia: a unitary pathophysiological model. J Psychiatr Res 1999; 33: 513-21.
    CrossrefPubMedGoogle Scholar
  • 37 Keshavan MS, Haas G, Miewald J, Montrose DM, Reddy R, Schooler NR, Sweeney JA. Prolonged untreated illness duration from prodromal onset predicts outcome infirst episode psychoses. Schizophr Bull 2003; 29: 757-69.
    CrossrefPubMedGoogle Scholar
  • 38 Kissling W, Seemann U, Müller P, Rüther E, Trenckmann U, Uber A, Glaser P, Glaser Th, Mast O, Schmidt D. Die indirekten und direkten Kosten der Schizophrenie. Fortschr Neurol Psychiat 1999; 67: 29-36.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Klosterkötter J, Schultze-Lutter F. Is there a primary prevention of schizophrenic psychosis?. Fortschr Neurol Psychiat 2001; 69: 104-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004; 184: 509-16.
    CrossrefPubMedGoogle Scholar
  • 41 Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. Br J Psychiatry Suppl 1998; 172: 45-52.
    CrossrefPubMedGoogle Scholar
  • 42 Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001; 50: 884-97.
    CrossrefPubMedGoogle Scholar
  • 43 Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000; 18: 106-24.
    PubMedGoogle Scholar
  • 44 Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis and the course of early schizophrenia. Br J Psychiatry Suppl 1998; 172: 84-9.
    CrossrefPubMedGoogle Scholar
  • 45 Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992; 149: 1183-8.
    CrossrefPubMedGoogle Scholar
  • 46 Machleidt W, Lamprecht F, Rohde-Dachser C, Rose HK. Schizophrene Störungen???. In: Psychiatrie, Psychosomatik und Psychotherapie. 6 ed,. Vol Stuttgart New York: Georg Thieme Verlag; 1999
    Google Scholar
  • 47 Malla AK, Norman RM, Voruganti LP. Improving outcome in schizophrenia: the case for early intervention. Cmaj 1999; 160: 843-6.
    Google Scholar
  • 48 McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996; 22: 201-22.
    CrossrefPubMedGoogle Scholar
  • 49 McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull 1996; 22: 305-26.
    CrossrefPubMedGoogle Scholar
  • 50 McGorry PD, Singh BS. Schizophrenia: risk and possibility. In: Raphael B, Burrows GD. (Hrsg). Handbook of Studies on Preventive Psychiatry. Amsterdam: Elsevier 1995: 491-514.
    Google Scholar
  • 51 McGorry PD, Yung AR, Phillips LJ. The “closein” or ultra high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 2003; 29: 771-90.
    CrossrefPubMedGoogle Scholar
  • 52 McGorry PD. et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
    CrossrefPubMedGoogle Scholar
  • 53 McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004; 02: 13.
    CrossrefPubMedGoogle Scholar
  • 54 Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005; 162: 495-506.
    CrossrefPubMedGoogle Scholar
  • 55 Milev P, Ho BC, Arndt S, Nopoulos P, Andreasen NC. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. Biol Psychiatry 2003; 54: 608-15.
    CrossrefPubMedGoogle Scholar
  • 56 Miller TJ. et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the “prodromal” sample. Schizophr Res 2003; 61: 19-30.
    CrossrefPubMedGoogle Scholar
  • 57 Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med 2001; 31: 381-400.
    CrossrefPubMedGoogle Scholar
  • 58 Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry 2000; 34 Suppl: S164-9.
    CrossrefPubMedGoogle Scholar
  • 59 Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H. Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000; 57: 1053-8.
    CrossrefPubMedGoogle Scholar
  • 60 Remington G, Shammi C. The use of pharmacotherapy in the prodrome of schizophrenia. CNS Spectr 2004; 09: 579-86.
    CrossrefPubMedGoogle Scholar
  • 61 Robinson D. et al. Predictors of relapse following response froma first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-7.
    CrossrefPubMedGoogle Scholar
  • 62 Rössler W, SJ Knapp M. Die Kosten der Schizophrenie. Fortschr Neurol Psychiat 1998; 66: 496-504.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 63 Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003; 36 (Suppl. 03) S162-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Ruhrmann S. et al. Functional disability in the prodromal phase of psychosis. Eur Psychiatry 2004; 19: S11.
    Google Scholar
  • 65 Rund BR, Melle I, Friis S, Larsen TK, Midboe LJ, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan T. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry 2004; 161: 466-72.
    CrossrefPubMedGoogle Scholar
  • 66 Schuepbach D, Hill SK, Sanders RD, Hell D, Keshavan MS, Sweeney JA. Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: a 2-year follow up. Schizophr Bull 2004; 30: 837-48.
    CrossrefPubMedGoogle Scholar
  • 67 Scully PJ, Coakley G, Kinsella A, Waddington JL. Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in ‘static’ v ‘progressive’ profiles. Br J Psychiatry 1997; 171: 154-8.
    CrossrefPubMedGoogle Scholar
  • 68 Scully PJ, Coakley G, Kinsella A, Waddington JL. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 1997; 27: 1303-10.
    CrossrefPubMedGoogle Scholar
  • 69 Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in firstepisode and chronic schizophrenia. Am J Psychiatry 1996; 153: 519-25.
    CrossrefPubMedGoogle Scholar
  • 70 Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54: 508-16.
    CrossrefPubMedGoogle Scholar
  • 71 Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol Psychiatry 1999; 45: 1412-8.
    CrossrefPubMedGoogle Scholar
  • 72 Waddington JL, Youssef HA, Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995; 25: 849-57.
    CrossrefPubMedGoogle Scholar
  • 73 Wiersma D, Nienhuis FJ, Slooff CJ, Giel R. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75-85.
    CrossrefPubMedGoogle Scholar
  • 74 Woods SW. et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453-64.
    CrossrefPubMedGoogle Scholar
  • 75 Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325-51.
    CrossrefPubMedGoogle Scholar
  • 76 Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med 1997; 27: 261-8.
    CrossrefPubMedGoogle Scholar
  • 77 Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up ofa highrisk (“prodromal”) group. Schizophr Res 2003; 60: 21-32.
    CrossrefPubMedGoogle Scholar